Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Neutral 72.4%

Neg 0% Neu 72.4% Pos 0%

Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and lowers the price target from $5 to $4.